Switch theme
Sign up to access all valuation multiples
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
2003
2.2K+
LTM Revenue $2.4B
LTM EBITDA $123M
$29.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alnylam Pharmaceuticals has a last 12-month revenue of $2.4B and a last 12-month EBITDA of $123M.
In the most recent fiscal year, Alnylam Pharmaceuticals achieved revenue of $2.2B and an EBITDA of -$179M.
Alnylam Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alnylam Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.8B | $2.2B | XXX | XXX | XXX |
| Gross Profit | $869M | $1.5B | XXX | XXX | XXX |
| Gross Margin | 48% | 68% | XXX | XXX | XXX |
| EBITDA | -$215M | -$179M | XXX | XXX | XXX |
| EBITDA Margin | -12% | -8% | XXX | XXX | XXX |
| Net Profit | -$1.1B | -$440M | XXX | XXX | XXX |
| Net Margin | -62% | -20% | XXX | XXX | XXX |
| Net Debt | $151M | $208M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Alnylam Pharmaceuticals's stock price is $240.
Alnylam Pharmaceuticals has current market cap of $31.1B, and EV of $29.7B.
See Alnylam Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29.7B | $31.1B | XXX | XXX | XXX | XXX | $-2.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Alnylam Pharmaceuticals has market cap of $31.1B and EV of $29.7B.
Alnylam Pharmaceuticals's trades at 12.2x LTM EV/Revenue multiple, and 241.4x LTM EBITDA.
Analysts estimate Alnylam Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Alnylam Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $29.7B | XXX | XXX | XXX |
| EV/Revenue | 13.2x | XXX | XXX | XXX |
| EV/EBITDA | -165.9x | XXX | XXX | XXX |
| P/E | -111.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -696.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAlnylam Pharmaceuticals's NTM/LTM revenue growth is 28%
Alnylam Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Alnylam Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Alnylam Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Alnylam Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -8% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -17% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 20% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 43% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 50% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 93% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alnylam Pharmaceuticals acquired XXX companies to date.
Last acquisition by Alnylam Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Alnylam Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Alnylam Pharmaceuticals founded? | Alnylam Pharmaceuticals was founded in 2003. |
| Where is Alnylam Pharmaceuticals headquartered? | Alnylam Pharmaceuticals is headquartered in United States of America. |
| How many employees does Alnylam Pharmaceuticals have? | As of today, Alnylam Pharmaceuticals has 2.2K+ employees. |
| Who is the CEO of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals's CEO is Dr. Yvonne L Greenstreet, MB.Ch.B.. |
| Is Alnylam Pharmaceuticals publicy listed? | Yes, Alnylam Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals trades under ALNY ticker. |
| When did Alnylam Pharmaceuticals go public? | Alnylam Pharmaceuticals went public in 2004. |
| Who are competitors of Alnylam Pharmaceuticals? | Similar companies to Alnylam Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals's current market cap is $31.1B |
| What is the current revenue of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals's last 12-month revenue is $2.4B. |
| What is the current EBITDA of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals's last 12-month EBITDA is $123M. |
| What is the current EV/Revenue multiple of Alnylam Pharmaceuticals? | Current revenue multiple of Alnylam Pharmaceuticals is 12.2x. |
| What is the current EV/EBITDA multiple of Alnylam Pharmaceuticals? | Current EBITDA multiple of Alnylam Pharmaceuticals is 241.4x. |
| What is the current revenue growth of Alnylam Pharmaceuticals? | Alnylam Pharmaceuticals revenue growth between 2023 and 2024 was 23%. |
| Is Alnylam Pharmaceuticals profitable? | Yes, Alnylam Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
